CONCLUSIONS Posterior chamber PIOLs represent a viable option in the treatment of mild to moderate and stable corneal ectasia in patients with contact lens intolerance who have low irregular astigmatism, a clear central cornea, and good preoperative corrected distance visual acuity. Quality of vision remained unaffected and no significant complications were reported in any of the studies. All studies showed a favorable refractive outcome. RESULTS A total of 30 relevant studies (13 prospective, 13 retrospective, 4 case reports) on the subject were studied and summarized. In addition, visual quality, corneal biomechanical outcomes, complications, the role of posterior chamber PIOL in combination treatment, and comparison of posterior chamber PIOL with other PIOLs for ectasias were also evaluated. All pertinent studies were reviewed, and the relevant articles were studied in detail for efficacy, stability, predictability, and safety outcomes. METHODS A review of the literature was conducted using the relevant keywords from various databases up to August 15, 2020. Also, you can see white lipid deposit, vessels growing into the area. The etiology of this condition is not understood, but classically these eyes present with a band of thinning with a step-off toward the center. This is when the cornea thins at the edges toward the limbus. Current research is promising, but long-term studies are essential to understand how the new protocols may affect corneal stability.read more read lessĪbstract: PURPOSE To summarize the indications and outcomes of posterior chamber phakic intraocular lens (PIOL) implantation in corneal ectasias including keratoconus, pellucid marginal degeneration (PMD), post-refractive surgery, and post-keratoplasty ectasias. 41 This video shows an eye with Terrien’s Marginal Degeneration. Summary Newer CXL protocols attempt to make the procedure safer and more effective. In addition, transepithelial crosslinking protocols have been designed with the goal of reducing postoperative pain and lower the risk of infectious complications of epithelial-off conventional protocols. ![]() Pulsed protocols may increase the long-term efficacy of the accelerated designs. Accelerated protocols have shown success to date, but there are concerns for long-term corneal stability. Recent findings Accelerated CXL protocols have the goal of delivering the same ultraviolet A intensity as conventional protocols, but over a shorter time period. New research is focused on modifying current treatment protocols with the goals of maximizing corneal stability while also shortening overall procedure time. The benefits of CXL have been well documented. Abstract: Purpose of review Corneal collagen crosslinking (CXL) is a minimally invasive treatment that can stabilize corneal ectatic disorders including keratoconus, pellucid marginal degeneration, or postrefractive surgery ectasia.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |